# A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors

> **NCT07749586** · PHASE1,PHASE2 · RECRUITING · sponsor: **Arvinas Inc.** · enrollment: 499 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** ARV-6723
- **DRUG:** Pembrolizumab
- **DRUG:** SOC

## Key facts

- **NCT ID:** NCT07749586
- **Lead sponsor:** Arvinas Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-29
- **Primary completion:** 2031-03-31
- **Final completion:** 2032-03-31
- **Target enrollment:** 499 (ESTIMATED)
- **Last updated:** 2026-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07749586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07749586, "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07749586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*